Am­gen rips off its $10B M&A cap, look­ing for deals “large and small”

You can put Am­gen $AMGN on the list of biotech’s big game hunters.

In their quar­ter­ly meet­ing with an­a­lysts Thurs­day, Am­gen CEO Bob Brad­way said his $40 bil­lion cache of cash gives him the flex­i­bil­i­ty to take a hard look at a va­ri­ety of ac­qui­si­tions this year, big and small.

For some time, Am­gen set a $10 bil­lion cap on deals, which is about what it paid for Onyx. This time? There isn’t a cap.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.